VUKOTIC, Ranka
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.930
AS - Asia 2.015
EU - Europa 1.615
SA - Sud America 264
AF - Africa 67
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 4
Totale 7.900
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.849
SG - Singapore 647
CN - Cina 448
PL - Polonia 324
HK - Hong Kong 305
GB - Regno Unito 292
VN - Vietnam 282
SE - Svezia 195
BR - Brasile 189
IT - Italia 175
FI - Finlandia 174
DE - Germania 102
RU - Federazione Russa 102
KR - Corea 63
IN - India 43
BG - Bulgaria 39
CA - Canada 39
UA - Ucraina 34
BD - Bangladesh 32
ES - Italia 31
FR - Francia 29
TR - Turchia 29
JP - Giappone 27
AR - Argentina 26
ID - Indonesia 26
NL - Olanda 24
ZA - Sudafrica 24
AE - Emirati Arabi Uniti 20
IQ - Iraq 18
MX - Messico 17
CZ - Repubblica Ceca 15
AT - Austria 13
CO - Colombia 11
VE - Venezuela 11
LT - Lituania 10
MA - Marocco 10
PH - Filippine 9
RO - Romania 9
CL - Cile 8
EG - Egitto 8
MY - Malesia 8
PK - Pakistan 8
DZ - Algeria 7
ET - Etiopia 7
PE - Perù 7
CR - Costa Rica 6
DO - Repubblica Dominicana 6
SA - Arabia Saudita 6
AL - Albania 5
AU - Australia 5
BE - Belgio 5
CH - Svizzera 5
GR - Grecia 5
IE - Irlanda 5
IL - Israele 5
PY - Paraguay 5
TN - Tunisia 5
UZ - Uzbekistan 5
JO - Giordania 4
PR - Porto Rico 4
QA - Qatar 4
A2 - ???statistics.table.value.countryCode.A2??? 3
EE - Estonia 3
GE - Georgia 3
KH - Cambogia 3
KZ - Kazakistan 3
RS - Serbia 3
TH - Thailandia 3
UY - Uruguay 3
BO - Bolivia 2
EC - Ecuador 2
GT - Guatemala 2
HR - Croazia 2
IR - Iran 2
MT - Malta 2
NI - Nicaragua 2
NP - Nepal 2
PT - Portogallo 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
TW - Taiwan 2
AM - Armenia 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BY - Bielorussia 1
CD - Congo 1
CI - Costa d'Avorio 1
CU - Cuba 1
CV - Capo Verde 1
CY - Cipro 1
DK - Danimarca 1
GA - Gabon 1
GD - Grenada 1
HN - Honduras 1
JM - Giamaica 1
KW - Kuwait 1
LB - Libano 1
LV - Lettonia 1
MC - Monaco 1
Totale 7.893
Salva come PNG Salva come JPEG
Città #
Santa Clara 531
Ashburn 448
Singapore 438
Warsaw 319
Fairfield 313
Chandler 302
Hong Kong 301
Helsinki 168
Nyköping 157
Houston 156
San Jose 129
Woodbridge 124
Wilmington 112
Cambridge 108
Southend 104
Beijing 102
London 98
Seattle 97
Ho Chi Minh City 89
Chicago 84
Los Angeles 84
Hanoi 73
New York 63
Council Bluffs 60
Seoul 55
The Dalles 54
San Diego 52
Hefei 51
Ann Arbor 49
Moscow 46
Dearborn 44
Salt Lake City 44
Princeton 41
Sofia 38
Orem 36
Jacksonville 31
Modena 30
Shanghai 28
São Paulo 26
Tokyo 24
Milan 22
Buffalo 20
Da Nang 20
Frankfurt am Main 20
Jakarta 20
Palma 18
Haiphong 16
Jersey City 16
Redwood City 16
Dallas 15
Tampa 14
Izmir 13
Brno 12
Vancouver 12
Brooklyn 11
Elk Grove Village 11
Johannesburg 11
Wuhan 11
Baghdad 10
Belo Horizonte 10
Bremen 10
Guangzhou 10
Nanjing 10
Redondo Beach 10
Sterling 10
Berlin 9
Bologna 9
Chennai 9
Denver 9
Falls Church 9
Grafing 9
Kilburn 9
Toronto 9
Augusta 8
Cairo 8
Chiswick 8
Eugene 8
Miano 8
Montreal 8
Vienna 8
Addis Ababa 7
Amsterdam 7
Groningen 7
Istanbul 7
Lauterbourg 7
Poplar 7
Riverside 7
San Francisco 7
Stanford 7
Brasília 6
Campinas 6
Dubai 6
Düsseldorf 6
Hounslow 6
Norwalk 6
Rijnsburg 6
Rosario 6
Southend-on-Sea 6
West Jordan 6
Athens 5
Totale 5.713
Salva come PNG Salva come JPEG
Nome #
AISF position paper on liver transplantation and pregnancy: Women in Hepatology Group, Italian Association for the Study of the Liver (AISF) 619
Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis 406
ANTICOAGULANT THERAPY IS SAFE AND EFFECTIVE IN PREVENTING PORTAL VEIN THROMBOSIS (PVT) IN ADVANCED CIRRHOTIC PATIENTS: A PROSPECTIVE RANDOMIZED CONTROLLED STUDY 386
Peginterferon-Α_2B plus ribavirin is more effective than peginterferon-Α_2A plus ribavirin in menopausal women with chronic hepatitis C 375
ENOXAPARIN PREVENTS PORTAL VEIN THROMBOSIS (PVT) AND DECOMPENSATION IN ADVANCED CIRRHOTIC PATIENTS: FINAL REPORT OF A PROSPECTIVE RANDOMIZED CONTROLLED STUDY 298
Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals 298
Reproductive status is associated with the severity of fibrosis in women with hepatitis C. 290
Hemodynamic response to propranolol in patients with recurrent hepatitis C virus-related cirrhosis after liver transplantation: A case-control study 247
Cryptogenic cholestasis in young and adults: ATP8B1, ABCB11, ABCB4, and TJP2 gene variants analysis by high-throughput sequencing 230
Development of different psychiatric manifestations during antiviral therapy for chronic hepatitis C. 205
Prospective, observational real-life study on eligibility for and outcomes of antiviral treatment with peginterferon α plus ribavirin in chronic hepatitis C 201
5-MTHF enhances the portal pressure reduction achieved with propranolol in patients with cirrhosis: A randomized placebo-controlled trial 200
Clinical and serological profile of primary biliary cirrhosis in men 199
Accuracy of elastography point quantification and steatosis influence on assessing liver fibrosis in patients with chronic hepatitis C 184
Familial intrahepatic cholestasis: New and wide perspectives 183
Assessment of Liver Fibrosis With Elastography Point Quantification vs Other Noninvasive Methods 180
Calcineurin inhibitors levels reduction during treatment with Sofosbuvir in liver transplanted patients 176
De novo autoimmune hepatitis in liver transplant: State-of-the-art review 163
Clinical Impact and Safety of Anticoagulants for Portal Vein Thrombosis in Cirrhosis 163
Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B ‘e’ antigen-negative chronic hepatitis B genotype D 160
The Effect of Liraglutide on β-Blockade for Preventing Variceal Bleeding: A Case Series 159
Serum hepatitis B core-related antigen is an effective tool to categorize patients with HBeAg-negative chronic hepatitis B 159
Bone marrow derived stem cells for the treatment of end-stage liver disease 154
In vitro effect of thymosin-alpha1 and interferon-alpha on Th1 and Th2 cytokine synthesis in patients with eAg-negative chronic hepatitis B 151
Hepatitis C Virus Core Antigen (HCVAg): An affordable assay to monitor the efficacy of treatment in DAAs era 150
Monitoring the treatment of hepatitis C with directly acting antivirals by serological and molecular methods 146
Current and forthcoming perspectives in linkage to care of hepatitis C virus infection: Assessment of an Italian focus group 144
Hepatitis B virus and immune response 140
Hepatitis C virus recurrence after liver transplantation: a 10-year evaluation 135
Safety and efficacy of direct-acting antivirals for the treatment of chronic hepatitis C in a real-world population aged 65 years and older 133
Impact of psychosocial status on liver transplant process 127
Insights into cancer severity from biomolecular interaction mechanisms 126
Hepatitis C virus eradication in the elderly: The challenge worth a long-life elixir? 120
Hepatocellular carcinoma appearance in patients with hepatitis C virus-related chronic liver disease 90 and 70 months after sustained virological response to interferon and ribavirin 117
The increase of Ribavirin dose improves sustained virological response in HCV-Genotype 1 patients with a partial response to PEG-Interferon and Ribavirin. 117
Vitamin E for the treatment of E-antigen-positive chronic hepatitis B in paediatric patients: results of a randomized phase 2 controlled study 116
Transient elastography in healthy subjects and factors influencing liver stiffness in non-alcoholi fatty liver disease: an Italian community-based population study 115
Role of circulating microRNAs to predict hepatocellular carcinoma recurrence in patients treated with radiofrequency ablation or surgery 115
Secondary prophylaxis of hepatocellular carcinoma: the comparison of direct-acting antivirals with pegylated interferon and untreated cohort 114
Long-term outcomes of direct acting antivirals in post-transplant advanced hepatitis C virus recurrence and fibrosing cholestatic hepatitis 108
Managing HCV treatment failure and the potential of resistance testing in informing second-line therapy options 107
Diagnostic Performance of PIVKA-II in Italian Patients with Hepatocellular Carcinoma 52
Totale 7.968
Salva come PNG Salva come JPEG
Categoria #
all - tutte 35.154
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 35.154
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021146 0 0 0 0 0 0 0 0 0 0 127 19
2021/2022726 58 30 40 40 16 51 23 87 83 77 123 98
2022/2023746 108 105 69 78 74 114 11 67 81 4 21 14
2023/2024455 21 25 27 70 102 21 43 47 5 6 21 67
2024/20251.530 47 12 4 121 353 241 67 121 171 102 118 173
2025/20263.301 188 63 165 322 535 547 406 191 389 376 119 0
Totale 7.968